Fecal Microbiota Transplantation in the Treatment of Inflammatory Bowel Disease (FMT-IBD)
Fecal Microbiota Transplantation in the Treatment of Inflammatory Bowel Disease: the Role of Selection of the Dai Ethnic Group as Donor Source in Terms of Treatment Efficacy and Pathogenic Mechanisms
Sponsor: Chinese University of Hong Kong
This NA trial investigates Fecal Microbiota Transplantation and is currently ongoing. Chinese University of Hong Kong leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Apr 2023 — Jul 2024 [monthly]
Unknown Status NA
-
Feb 2023 — Apr 2023 [monthly]
Unknown Status NA
Status: Enrolling By Invitation → Unknown Status
-
Jan 2021 — Feb 2023 [monthly]
Enrolling By Invitation NA
▶ Show 1 earlier version
-
Jul 2020 — Jan 2021 [monthly]
Enrolling By Invitation NA
First recorded
Sep 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chinese University of Hong Kong
- First Affiliated Hospital of Kunming Medical University
For direct contact, visit the study record on ClinicalTrials.gov .